Healthcare
Live Price
Offline$28.18
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 252 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sundrug Co.,Ltd. (SDGCF) is a Healthcare stock with a market cap of $440.32B and listed on OTC. The stock last traded around $28.18 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +6.7%, EPS growth of +5.6%, a dividend yield of 3.5%. What stands out right now is revenue +6.7%, EPS +5.6%, free cash flow +132.8% with operating margin 5.5% and ROIC 9.3%. The dividend matters to the case here, with a current yield around 3.5%. Valuation is more restrained than many high-expectation growth names at P/E 14.1 and price/sales 0.5. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SDGCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SDGCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SDGCF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SDGCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$634.3B
-2.2% YoY
FY Net Income
$25.3B
+6.2% YoY
Free Cash Flow
$138.3M
+41.6% YoY
Revenue Growth
+6.7%
EPS Growth
+5.6%
Gross Margin
25.0%
Net Margin
3.7%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 801.8B | 751.8B | 690.5B | 648.7B | 634.3B |
| Gross Profit | 204.1B | 189.3B | 1.3B | 1.3B | 1.4B |
| Operating Income | 44.5B | 41.0B | 37.5B | 34.1B | 37.3B |
| EBITDA | 61.0B | 56.1B | 49.8B | 44.9B | 45.9B |
| Net Income | 30.8B | 29.1B | 25.7B | 23.9B | 25.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 65.0B | 69.7B | 80.9B | 89.3B | 86.5B |
| Total Assets | 444.0B | 420.2B | 2.7B | 2.7B | 2.8B |
| Total Liabilities | 174.3B | 167.1B | 944M | 864M | 935M |
| Shareholder Equity | 269.7B | 253.1B | 236.3B | 220.6B | 205.2B |
| Total Debt | 38.7B | 35.0B | 7M | 4M | 1M |
| Net Debt | -26.3B | -34.7B | -80.9B | -89.3B | -86.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
287M
+10.4% YoY
Capital Expenditures
149M
+8.3% YoY
Free Cash Flow
138M
+41.6% YoY
Key ratios
Gross Margin
25.0%
Operating Margin
5.5%
Net Margin
3.7%
ROE
11.4%
Debt / Equity
0.18x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.